Kymriah

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:CAR_T-cell_therapy
gptkbp:administration_setting hospital or clinic
gptkbp:adverse_effect_management monitoring required
gptkbp:approves gptkb:large_B-cell_lymphoma
gptkb:2017
gptkb:Oncology
gptkbp:associated_with T-cell activation
immune response
tumor lysis syndrome
B-cell aplasia
gptkbp:clinical_trial gptkb:ECOG-ACRIN_E1910
gptkb:ELIANA
Phase 2
ZUMA-1
gptkbp:collaboration academic institutions
research organizations
gptkbp:competitors biologic therapies
other CAR T therapies
gptkbp:developed_by gptkb:Novartis
gptkbp:dosage_form once
gptkbp:duration single infusion
gptkbp:eligibility age 25 or younger
relapsed or refractory disease
gptkbp:emaapproval_date September 2018
gptkbp:financial_support gptkb:educational_resources
financial assistance programs
gptkbp:funding gptkb:pharmaceuticals
gptkbp:future_prospects combination therapies
long-term effects studies
gptkbp:healthcare August 30, 2017
https://www.w3.org/2000/01/rdf-schema#label Kymriah
gptkbp:indication B-cell malignancies
gptkbp:is_monitored_by post-infusion monitoring
gptkbp:manufacturer gptkb:Novartis_Pharmaceuticals_Corporation
gptkbp:marketed_as gptkb:Kymriah
gptkbp:mechanism_of_action genetically modified T cells
gptkbp:origin gptkb:USA
gptkbp:patient_population pediatric and young adult patients
gptkbp:price approximately $373,000
gptkbp:provides_guidance_on ASCO guidelines
specialized cancer centers
NCCN guidelines
gptkbp:publication peer-reviewed journals
clinical trial results
gptkbp:regulatory_compliance approved
gptkbp:research_areas oncology
gptkbp:route_of_administration intravenous infusion
gptkbp:side_effect cytokine release syndrome
neurological events
gptkbp:storage frozen
gptkbp:targets gptkb:CD19
gptkbp:treatment remission
improved survival rates
quality of life improvement
high response rate
durable remission
gptkbp:type personalized medicine
gptkbp:bfsParent gptkb:Novartis
gptkbp:bfsLayer 4